Severe hypercholesterolaemia: Therapeutic goals and eligibility criteria for LDL apheresis in Europe

Current Opinion in Lipidology

Volumn 21, Issue 6, 2010, Pages 492-498

  Thompson, Gilbert R ^a   Catapano, Alberico ^b   Saheb, Samir ^c   Atassi Dumont, Marielle ^c   Barbir, Mahmoud ^d   Eriksson, Mats ^e   Paulweber, Bernhard ^f   Sijbrands, Eric ^g   Stalenhoef, Anton F ^h   Parhofer, Klaus G ⁱ  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MILAN   (Italy)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f St Johanns Spital   (Austria)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

LDL apheresis; LDL cholesterol; severe familial hypercholesterolaemia

Indexed keywords

EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; SIMVASTATIN;

APHERESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; EUROPE; FAMILIAL HYPERCHOLESTEROLEMIA; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HUMAN; HYPERCHOLESTEROLEMIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEVERE HYPERCHOLESTEROLEMIA;

ADULT; BLOOD COMPONENT REMOVAL; CARDIOVASCULAR DISEASES; CHILD; CHOLESTEROL, LDL; ELIGIBILITY DETERMINATION; EUROPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 78650417876     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3283402f53     Document Type: Review

References (50)

1. National Institutes of Health. National Heart, Lung, and Blood Institute. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. NIH Publication No. 02-5215. 2002.
2. Goldstein JL, Kita T, Brown MS. Defective lipoprotein receptors and atherosclerosis. Lessons from an animal counterpart of familial hypercholesterolemia. N Engl J Med 1983; 309:288-296.
3. De Sauvage Nolting PR, Defesche JC, Buirma RJ, et al. Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia. J Intern Med 2003; 253:161-168.
4. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14 (Suppl. 2):S1-S113.
5. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipi-demic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160:459-467.
6. O'Neill FH, Patel DD, Knight BL, et al. Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2001; 21:832-837.
7. Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999; 83:1303-1307.
8. Sloan KL, Sales AE, Willems JP, et al. Frequency of serum low-density lipoprotein cholesterol measurement and frequency of results <100mg/dl among patients who had coronary events (Northwest VA Network Study) Am J Cardiol 2001 88 1143-1146
9. Wierzbicki AS, Humphries SE, Minhas R. Familial hypercholesterolaemia: summary of NICE guidance. BMJ 2008; 337:a1095.
10. Marais AD. Familial hypercholesterolaemia. Clin Biochem Rev 2004; 25:49-68.
11. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1992; 1:445-466.
12. Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest 2003; 111:1795-1803.
13. Umans-Eckenhausen MA, Sijbrands EJ, Kastelein JJ, Defesche JC. Low-density lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population. Circulation 2002; 106:3031-3036.
14. Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004; 173:55-68.
15. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009; 301:2331-2339.
16. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009; 361:251 8-2528.
17. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry PL et al. Lipoprotein (a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302:412-423.
18. Kolansky DM, Cuchel M, Clark BJ, et al. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am J Cardiol 2008; 102:1438-1443.
19. Palcoux JB, Atassi-Dumont M, Lefevre P, et al. Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years. Ther Apher Dial 2008; 12:195-201.
20. Rallidis L, Naoumova RP, Thompson GR, Nihoyannopoulos P. Extent and severity of atherosclerotic involvement of the aortic valve and root in familial hypercholesterolaemia. Heart 1998; 80:583-590.
21. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008; 337:a2423.
22. Rodenburg J, Vissers MN, Wiegman A, et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation 2007; 116:664-668.
23. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357:577-581.
24. Wiegman A, Hutten BA, deGroot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2004; 292:331-337.
25. Backes JM, Gibson CA, Howard PA. Optimal lipid modification: the rationale for combination therapy. Vasc Health Risk Manag 2005; 1:317-331.
26. Kermani T, Frishman WH. Nonpharmacologic approaches for the treatment of hyperlipidemia. Cardiol Rev 2005; 13:247-255.
27. Pijlman AH, Huijgen R, Verhagen SN, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in the Netherlands. Atherosclerosis 2010; 209:189-194.
28. Webb JC, Sun XM, McCarthy SN, et al. Characterization of mutations in the low density lipoprotein (LDL)-receptor gene in patients with homozygous familial hypercholesterolemia, and frequency of these mutations in FH patients in the United Kingdom. J Lipid Res 1996; 37:368-381.
29. Grundy SM, Cleeman JI, MerzCN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227-239.
30. Moriarty PM. LDL-apheresis Therapy. Curr Treat Options Cardiovasc Med 2006; 8:282-288.
31. Mehta PK, Baer J, Nell C, Sperling LS. Low-density lipoprotein apheresis as a treatment option for hyperlipidemia. Curr Treat Options Cardiovasc Med 2009; 11:279-288.
32. Thompson GR. Recommendations for the use of LDL apheresis. Atherosclerosis 2008; 198:247-255.
33. Marais AD, Naoumova RP, Firth JC, et al. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J Lipid Res 1997; 38:2071-2078.
34. Pfohl M, Naoumova RP, Klass C, et al. Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy. J Lipid Res 1994; 35:1946-1955.
35. Kroon AA, van't Hof MA, Demacker PN, Stalenhoef AF. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. Atherosclerosis 2000; 152:519-526.
36. Thompson GR, Barbir M, Davies D, et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 2010; 208:317-321.
37. Bohl S, Kassner U, Eckardt R, et al. Single lipoprotein apheresis session improves cardiac microvascular function in patients with elevated lipoprotei n(a): detection by stress/rest perfusion magnetic resonance imaging. Ther Apher Dial 2009; 13:129-137.
38. Awan Z, Alrasadi K, Francis GA, et al. Vascular calcifications in homozygote familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2008; 28:777-785.
39. Benlian P. Genes of lipoprotein metabolism. In: Genetics of dyslipidemia. London: Kluwer Academic Publishers; 2001. pp. 41 -181.
40. Mabuchi H, Koizumi J, Shimizu M, et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol 1998; 82:1489-1495.
41. Tselmin S, Julius U, Muller G, et al. Cardiovascular events in patients with increased lipoprotein (a) - retrospective data analysis in an outpatient department of lipid disorders. Atheroscler Suppl 2009; 10:79-84.
42. Heigl F, Hettich R, Lotz N, et al. Indication and implementation of lipidapheresis, rheopheresis, or immunoadsorption (lessons learnt from Germany's largest apheresis center). Atheroscler Suppl 2009; 10:137-141.
43. Thompson GR. What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease? Atherosclerosis 1997; 131:1-5.
44. Agence Francaise de Securite Sanitaire des Produits de Sante. La prise en charge therapeutique du patient dyslipidemique - Recommandations. Saint Denis, France: Afsapps, September 2000.
45. Pottle A, Barbir M. Is there a place for LDL-apheresis in the management of raised cholesterol? Future Lipidol 2008; 3:1-3.
46. Norda R, Berseus O, Stegmayr B. Adverse events and problems in therapeutic hemapheresis. A report from the Swedish registry. Transfus Apher Sci 2001; 25:33-41.
47. Beigel R, Beigel Y. Homozygous familial hypercholesterolemia: long term clinical course and plasma exchange therapy for two individual patients and review of the literature. J Clin Apher 2009; 24:219-224.
48. BramlageCP, Armstrong VW, Zapf A, et al. Low-density lipoprotein apheresis decreases ferritin, transferrin and vitamin B12, which may cause anemia in serially treated patients. Ther Apher Dial 2010; 14:136-142.
49. Kroon AA, Mol MJ, Stalenhoef AF. ACE inhibitors and LDL-apheresis with dextran sulphate adsorption. Lancet 1992; 340:1476.
50. Morelli F, Carlier P, Giannini G, et al. Hypercholesterolemia and LDL apheresis. Int J Artif Organs 2005; 28:1025-1031.